NASDAQ:RNAC Cartesian Therapeutics (RNAC) Stock Price, News & Analysis $5.89 -0.41 (-6.51%) Closing price 04:00 PM EasternExtended Trading$5.90 +0.00 (+0.08%) As of 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Cartesian Therapeutics Stock (NASDAQ:RNAC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cartesian Therapeutics alerts:Sign Up Key Stats Today's Range$5.80▼$6.3350-Day Range$6.08▼$8.4352-Week Range$5.60▼$11.00Volume314,575 shsAverage Volume191,325 shsMarket Capitalization$179.65 millionP/E RatioN/ADividend YieldN/APrice Target$32.60Consensus RatingModerate Buy Company Overview Cartesian Therapeutics is a clinical-stage biotechnology company developing RNA-engineered cell therapies for autoimmune diseases and cancer. Its platform uses messenger RNA to program immune cells, including T cells, to recognize and target disease-associated cells. The company’s lead program, Descartes-08, is an autologous CAR T-cell therapy designed to target BCMA and being studied for generalized myasthenia gravis. Unlike gene-modified cell therapies that rely on permanent genetic changes, Cartesian’s approach uses RNA to produce temporary cell modifications. The company is also advancing other cell-therapy candidates for serious diseases. Cartesian became a publicly traded company through a merger with Selecta Biosciences, which adopted the Cartesian Therapeutics name. Its work remains focused on clinical development; its therapies are investigational and are not approved for commercial use.AI Generated. May Contain Errors. Read More Cartesian Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks33rd Percentile Overall ScoreRNAC MarketRank™: 1.668939187345 of 5 starsCartesian Therapeutics scored higher than 33% of companies evaluated by MarketBeat, and ranked 1299th out of 1,704 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingCartesian Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on no strong buy ratings, 5 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialCartesian Therapeutics has a consensus price target of $32.60, representing about 452.1% upside from its current price of $5.91.Amount of Analyst CoverageCartesian Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Cartesian Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Cartesian Therapeutics are expected to decrease in the coming year, from ($2.19) to ($3.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cartesian Therapeutics is -1.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cartesian Therapeutics is -1.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.09% of the float of Cartesian Therapeutics has been sold short.Short Interest Ratio / Days to CoverCartesian Therapeutics has a short interest ratio ("days to cover") of 16.5, which indicates bearish sentiment.Change versus previous monthShort interest in Cartesian Therapeutics has recently increased by 2.20%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCartesian Therapeutics does not currently pay a dividend.Dividend GrowthCartesian Therapeutics does not have a long track record of dividend growth. News and Social Media1.6 / 5News Sentiment-0.44 News SentimentCartesian Therapeutics has a news sentiment score of -0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.37 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Cartesian Therapeutics this week, compared to 3 articles on an average week.MarketBeat Follows2 people have added Cartesian Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cartesian Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders37.20% of the stock of Cartesian Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.95% of the stock of Cartesian Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cartesian Therapeutics' insider trading history. Receive RNAC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cartesian Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RNAC Stock News HeadlinesBears are losing control over Cartesian Therapeutics, Inc. (RNAC), here's why it's a buy nowNovember 16 at 1:44 PM | msn.comCartesian Therapeutics, Inc. (NASDAQ:RNAC) Stock Has Consensus Target Price of $32.60 According to BrokeragesNovember 12, 2026 | americanbankingnews.comI'm handing you this stock todayElon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.November 19 at 1:00 AM | Behind the Markets (Ad)FY2026 Earnings Forecast for RNAC Issued By HC WainwrightNovember 12, 2026 | americanbankingnews.comCartesian Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business UpdateNovember 5, 2026 | globenewswire.comCartesian Therapeutics Announces New Employment Inducement GrantNovember 3, 2026 | globenewswire.comCartesian: Maintaining 'Buy' On Descartes-08 MG Data Release And CAR-T AgreementOctober 29, 2026 | seekingalpha.comCartesian Therapeutics Announces New Employment Inducement GrantsOctober 2, 2026 | globenewswire.comSee More Headlines RNAC Stock Analysis - Frequently Asked Questions How have RNAC shares performed this year? Cartesian Therapeutics' stock was trading at $7.21 on January 1st, 2026. Since then, RNAC stock has decreased by 18.1% and is now trading at $5.9050. How were Cartesian Therapeutics' earnings last quarter? Cartesian Therapeutics, Inc. (NASDAQ:RNAC) posted its earnings results on Thursday, November, 5th. The company reported ($0.38) earnings per share for the quarter, topping analysts' consensus estimates of ($1.01) by $0.63. When did Cartesian Therapeutics' stock split? Cartesian Therapeutics shares reverse split on Friday, April 5th 2024.The 1-30 reverse split was announced on Friday, April 5th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did Cartesian Therapeutics IPO? Cartesian Therapeutics (RNAC) raised $75 million in an initial public offering (IPO) on Tuesday, June 21st 2016. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Who are Cartesian Therapeutics' major shareholders? Cartesian Therapeutics' top institutional investors include State Street Corp (0.86%), Marshall Wace LLP (0.80%), Privium Fund Management B.V. (0.51%) and Goldman Sachs Group Inc. (0.17%). Insiders that own company stock include Timothy A Springer, Blaine Davis, Metin Kurtoglu and Milos Miljkovic. View institutional ownership trends. How do I buy shares of Cartesian Therapeutics? Shares of RNAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cartesian Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cartesian Therapeutics investors own include Broadcom (AVGO), Eos Energy Enterprises (EOSE), Immunic (IMUX), Lantern Pharma (LTRN), Micron Technology (MU), NVIDIA (NVDA) and Zymeworks (ZYME). Company Calendar Last Earnings11/05/2026Today11/19/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 RNAC's financial health is in the Green zone, according to TradeSmith. RNAC has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:RNAC Previous SymbolNASDAQ:RNAC CIK1453687 Webwww.cartesiantherapeutics.com Phone617-923-1400Fax617-924-3454Employees75Year Founded2016Price Target and Rating Average Price Target for Cartesian Therapeutics$32.60 High Price Target$44.00 Low Price Target$16.00 Potential Upside/Downside+453.5%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($4.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$130.30 million Net Margins-8,550.65% Pretax Margin-13,332.10% Return on EquityN/A Return on Assets-23.63% Debt Debt-to-Equity RatioN/A Current Ratio8.38 Quick Ratio8.38 Sales & Book Value Annual Sales$2.80 million Price / Sales64.16 Cash FlowN/A Price / Cash FlowN/A Book Value($4.28) per share Price / Book-1.38Miscellaneous Outstanding Shares30,500,000Free Float19,156,000Market Cap$179.65 million OptionableOptionable Beta0.74 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:RNAC) was last updated on 11/19/2026 by MarketBeat.com Staff. From Our PartnersChase, Wells Fargo and Capital One all showed errors on Nov. 16On November 16, customers of Chase, Bank of America, Wells Fargo, Capital One and Zelle reported errors when t...Cedar Gold Group | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredA Bill Would Reprice America's Gold at Market ValueThe US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,00...Concord Gold Capital | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cartesian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cartesian Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.